Synthesis, Nicotinic Acetylcholine Receptor Binding, and in Vitro and in Vivo Pharmacological Properties of 2'-Fluoro-(substituted thiophenyl)deschloroepibatidine Analogues.

Autor: Ondachi PW; Research Triangle Institute , P.O. Box 12194, Research Triangle Park, North Carolina 27709, United States., Castro AH; Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami , Miami, Florida 33101, United States., Sherman B; Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami , Miami, Florida 33101, United States., Luetje CW; Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami , Miami, Florida 33101, United States., Damaj MI; Department of Pharmacology, Virginia Commonwealth University Medical Campus , P.O. Box 980615, Richmond, Virginia 23298-0613, United States., Mascarella SW; Research Triangle Institute , P.O. Box 12194, Research Triangle Park, North Carolina 27709, United States., Navarro HA; Research Triangle Institute , P.O. Box 12194, Research Triangle Park, North Carolina 27709, United States., Carroll FI; Research Triangle Institute , P.O. Box 12194, Research Triangle Park, North Carolina 27709, United States.
Jazyk: angličtina
Zdroj: ACS chemical neuroscience [ACS Chem Neurosci] 2017 Jan 18; Vol. 8 (1), pp. 115-127. Date of Electronic Publication: 2016 Oct 20.
DOI: 10.1021/acschemneuro.6b00252
Abstrakt: The synthesis, nAChR in vitro and in vivo pharmacological properties of 2'-fluoro-3'-(substituted thiophenyl)deschloroepibatidine analogues (5a-f, 6a-d, and 7a-c) are presented herein. All had subnanomolar affinity at α4β2*-nAChRs. Contrary to lead structure epibatidine, a potent nAChR agonist, all were potent α4β2- and α3β4-AChR antagonists in an in vitro functional assay. In vivo, the compounds were also nAChR antagonists with various degrees of agonist activity. Compounds 5e, 5f, 6a, 6c, 6d, and 7c had no agonist effects in the tail-flick, hot-plate, hypothermia, or spontaneous activity tests, whereas 5a-d, 7a and 7b did not have agonist activity in the tail-flick and hot-plate tests but, like varenicline, were agonists in the hypothermia and spontaneous activity tests. Compound 6b had agonist activity in all four in vivo tests. All the compounds were antagonists of nicotine-induced antinociception in the tail-flick test, and all except 5c, 5d, 5f, and 6b were antagonists of nicotine-induced antinociception in the hot-plate test. Compound 7c, which had a K i = 0.86 nM in the binding assay similar potency at α4β2/α3β4 with selectivity relative to α7 nAChRs, had an AD 50 value of 0.001 μg/kg in the tail-flick test with no agonist activity in the in vitro or in vivo test had one of the more interesting profiles.
Databáze: MEDLINE